Posts

Contineum–J&J depression drug misses Phase 2 trial goal

on

Novartis stock drops after Avidity centerpiece fails Phase 3 trial

on

Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta

on

Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3

on

Novo Nordisk's Semaglutide Misses Key Goals in Closely-Watched Alzheimer’s Disease Phase 3 Trials

on

Korro Bio Abandons Lead Genetic Disease Drug Candidate KRRO-110 After Disappointing Trial Data

on

Sarepta's Duchenne Muscular Dystrophy Drugs Fail Confirmatory Trial, Company Pursues Full FDA Approval Regardless

on

Moderna Halts Development of CMV Vaccine After Phase 3 Failure

on

Eye Disease Biotech Kala Bio Collapses After Failed Clinical Trial, Lender Takes Control

on

Alector's GSK-partnered dementia drug latozinemab fails in late-stage trial

on

Neuphoria Scraps Social Anxiety Drug After Trial Failure; Minerva Doubles Down on Schizophrenia Therapy

on

Acadia Pulls Plug on Prader-Willi Drug After Phase 3 Trial Failure

on

Placebo Response Trips Up Harmony Biosciences’ Fragile X Drug in Late-Stage Phase 3 Trial

on

Acadia Halts Development of Nasal Prader-Willi Drug After Phase 3 Failure

on

J&J Halts Phase 2a Rheumatoid Arthritis Program for Imaavy (Nipocalimab) after Lackluster Results

on

Amylyx Discontinues Rare Disease Program After Relyvrio Fails to Show Benefit Over Placebo

on

Atai's Schizophrenia Drug Fails to Improve Cognition in Phase 2 Study

on

Viatris Ophthalmic Drug Fails Phase 3 for Blepharitis; Company Weighs Next Steps

on

AstraZeneca Amyloidosis Drug Fails Phase 3 Trials but Shows Potential in Subgroup

on

Taiho's Investigational DMD Therapy Misses Primary Endpoint in Phase 3 Trial

on